Discover

EDIT
Editas Medicine, Inc.
3.46
1 x 2.61
1 x 4.44
bid
ask
+
0.19
5.64%
12:11 PM
timesize
Ytd69.02%
1y35.35%
3.32
day range
3.68
1.66
52 week range
4.54
Open3.33Prev Close3.28Low3.32High3.68Mkt Cap531.75M
Vol2.22MAvg Vol2.36MEPS-1.14P/EN/AForward P/E-0.53
Beta2.01Short Ratio6.70Inst. Own70.94%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning05-0550-d Avg2.90200-d Avg2.681yr Est3.67

EDIT News

Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday
benzinga.com
Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday

Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery for

The Healthcare M&A Wave
forbes.com
The Healthcare M&A Wave

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Bioscienc

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
fool.com
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
globenewswire.com
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneerin

Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
benzinga.com
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks

Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries,

benzinga.com
Editas Medicine Prices $125M Public Offering Of 55.6M Shares And Warrants At $2.25 Each

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative med

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
globenewswire.com
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneerin

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga.com
Editas Medicine Launches Public Stock Offering to Raise Capital

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative med

Editas Medicine Announces Proposed Public Offering
globenewswire.com
Editas Medicine Announces Proposed Public Offering

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneerin

benzinga.com
Editas Reports Cholesterol-Lowering Results for Experimental Gene Therapy

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
globenewswire.com
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a),

Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-hu

benzinga.com
Editas Medicine Announces New Preclinical Data Supporting Continued Advancement Of Its In Vivo Devel

The data is being presented this week at the 2026 Annual Meeting of the American Society of Gene and

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
globenewswire.com
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatme

New data demonstrate promising preclinical safety profile and durable LDL-C lowering of ≥90% with si

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
zacks.com
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Editas narrows Q1 loss as costs fall, but revenues drop sharply. Pipeline focus shifts to in vivo ge

benzinga.com
Chardan Capital Maintains Buy on Editas Medicine, Raises Price Target to $4

Chardan Capital analyst Geulah Livshits maintains Editas Medicine (NASDAQ:EDIT) with a Buy and ra

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
zacks.com
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

Editas Medicine (EDIT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus

benzinga.com
Editas Medicine Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $2.831M Miss $4.065M Estimate

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.26) per share which beat the analyst

Editas Medicine Announces First Quarter 2026 Results and Business Updates
globenewswire.com
Editas Medicine Announces First Quarter 2026 Results and Business Updates

EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve e

benzinga.com
Editas Medicine To Present New Preclinical Data Demonstrating Progress Of EDIT-401 As Potential Trea

Five abstracts have been accepted for presentation, including one oral presentation and two poster p

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
globenewswire.com
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Trea

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneer

Why Investors Need to Take Advantage of These 2 Medical Stocks Now
zacks.com
Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should tak

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of “Moderate Buy” from Analysts
defenseworld.net
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Editas Medicine, Inc. (NASDAQ: EDIT - Get Free Report) have received an average rating of

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
zacks.com
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

JPMorgan Chase & Co. Has $2.85 Million Position in Editas Medicine, Inc. $EDIT
defenseworld.net
JPMorgan Chase & Co. Has $2.85 Million Position in Editas Medicine, Inc. $EDIT

JPMorgan Chase and Co. cut its holdings in Editas Medicine, Inc. (NASDAQ: EDIT) by 23.0% in the unde

benzinga.com
Editas Medicine Says USPTO Upholds PTAB Ruling Favoring Broad Institute In CRISPR Patent Interferenc

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo

benzinga.com
Editas Medicine Sees USPTO Reaffirm Broad Institute's CRISPR Patent Priority

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
globenewswire.com
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of

CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneer

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of “Moderate Buy” from Analysts
defenseworld.net
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Editas Medicine, Inc. (NASDAQ: EDIT - Get Free Report) have been given a consensus rating

Is Editas Medicine Going to $0?
fool.com
Is Editas Medicine Going to $0?

Editas Medicine has been on fire over the trailing-12-month period. However, the stock has been crus

benzinga.com
Jones Trading Upgrades Editas Medicine to Buy, Announces $8 Price Target

Jones Trading analyst Soumit Roy upgrades Editas Medicine (NASDAQ:EDIT) from Hold to Buy and anno

Editas Medicine Q4 Earnings Assessment
benzinga.com
Editas Medicine Q4 Earnings Assessment

benzinga.com
Editas Medicine Q4 EPS $(0.06) Beats $(0.25) Estimate, Sales $24.741M Beat $5.595M Estimate

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.06) per share which beat the analyst

benzinga.com
Editas Medicine Q3 EPS $(0.28) Beats $(0.29) Estimate, Sales $7.543M Beat $5.020M Estimate

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.28) per share which beat the analyst

benzinga.com
Editas Medicine To Present Data On LDL Cholesterol–Lowering In Vivo Crispr Gene Editing Medicine At

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transf

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles
benzinga.com
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a s

benzinga.com
Editas Medicine To Deliver EDIT-401 Oral Presentation At European Society Of Gene And Cell Therapy C

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years
benzinga.com
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potenti

benzinga.com
Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

benzinga.com
HC Wainwright & Co. Reiterates Buy on Editas Medicine, Maintains $5 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Editas Medicine (NASDAQ:EDIT) with

benzinga.com
Wells Fargo Maintains Equal-Weight on Editas Medicine, Raises Price Target to $4

Wells Fargo analyst Yanan Zhu maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and rai

benzinga.com
Editas Medicine Announces EDIT-401 As Lead In Vivo Candidate With ~90% LDL-C Reduction And Human Pro

EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primatesEDIT-401 on track

benzinga.com
HC Wainwright & Co. Maintains Buy on Editas Medicine, Raises Price Target to $5

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Editas Medicine (NASDAQ:EDIT) with a

benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

benzinga.com
Baird Maintains Outperform on Editas Medicine, Raises Price Target to $6

Baird analyst Joel Beatty maintains Editas Medicine (NASDAQ:EDIT) with a Outperform and raises th

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
benzinga.com
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a str

benzinga.com
Editas Medicine Reports 58% Mean HBG1/2 Promoter Editing At Five Months Using Single-Dose tLNP Deliv

Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, dem

benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga.com
Baird Maintains Outperform on Editas Medicine, Lowers Price Target to $4

Baird analyst Joel Beatty maintains Editas Medicine (NASDAQ:EDIT) with a Outperform and lowers th

benzinga.com
Editas Medicine Shares In Vivo Proof Of Concept Data Supporting Development Of Treatment For Undiscl

In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful R